- Home
- BCYC vs EVT Comparison
BCYC vs EVT Comparison
Compare BCYC & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- EVT
- Stock Information
- Founded
- BCYC 2009
- EVT 2003
- Country
- BCYC United Kingdom
- EVT United States
- Employees
- BCYC N/A
- EVT N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- BCYC Health Care
- EVT Finance
- Exchange
- BCYC Nasdaq
- EVT Nasdaq
- Market Cap
- BCYC 1.7B
- EVT 1.8B
- IPO Year
- BCYC 2019
- EVT N/A
- Fundamental
- Price
- BCYC $13.34
- EVT $24.41
- Analyst Decision
- BCYC Buy
- EVT
- Analyst Count
- BCYC 9
- EVT 0
- Target Price
- BCYC $34.50
- EVT N/A
- AVG Volume (30 Days)
- BCYC 417.9K
- EVT 121.5K
- Earning Date
- BCYC 02-18-2025
- EVT 01-01-0001
- Dividend Yield
- BCYC N/A
- EVT 7.72%
- EPS Growth
- BCYC N/A
- EVT N/A
- EPS
- BCYC N/A
- EVT N/A
- Revenue
- BCYC $36,898,000.00
- EVT N/A
- Revenue This Year
- BCYC $40.69
- EVT N/A
- Revenue Next Year
- BCYC N/A
- EVT N/A
- P/E Ratio
- BCYC N/A
- EVT N/A
- Revenue Growth
- BCYC 48.60
- EVT N/A
- 52 Week Low
- BCYC $12.17
- EVT $18.70
- 52 Week High
- BCYC $28.67
- EVT $23.82
- Technical
- Relative Strength Index (RSI)
- BCYC 34.88
- EVT 54.05
- Support Level
- BCYC $13.20
- EVT $23.63
- Resistance Level
- BCYC $15.43
- EVT $24.35
- Average True Range (ATR)
- BCYC 0.89
- EVT 0.29
- MACD
- BCYC 0.16
- EVT 0.07
- Stochastic Oscillator
- BCYC 6.17
- EVT 92.86
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.